Key insights
- Hims & Hers Health stock rallied following a significant open-market share purchase by a board director, signaling confidence in the company's prospects. This positive signal was partially offset by a BofA Securities price target cut due to concerns about the company's full-year outlook. The company's expansion into generic semaglutide in Canada and broader strategic initiatives also contributed to the stock's movement.
Investing.com -- Hims & Hers Health stock rose nearly 5.0% in morning trading after a board director’s substantial open-market share purchase, disclosed via an SEC filing, reignited investor confidence in the telehealth platform. Director David B. Wells acquired 48,400 shares on May 26, 2026, for an estimated $1.17 million, increasing his holdings in the company by approximately 27.5%. Wells, a former Netflix CFO and current Hims board member, made the purchase at roughly $24.235 per share.
The transaction is widely viewed as a vote of confidence from the board member in the telehealth company’s prospects, as insider buying can signal that company leadership believes the stock is undervalued or holds positive expectations for future performance. Adding some complexity to the picture, BofA Securities lowered its valuation multiple on HIMS shares and cut its price target, citing risks tied to the company’s full-year outlook — which calls for revenue between $2.8 billion and $3.0 billion alongside adjusted core profit of $275 million to $350 million. The analyst action tempered enthusiasm but did not derail the momentum generated by the insider buy.
Broader concerns about the sustainability of Hims’ GLP-1-driven momentum persist amid rising competition, though the company recently expanded its weight-loss offering by launching generic semaglutide in Canada — supplied by Apotex — following the early lapse of Novo Nordisk’s Canadian semaglutide patent. Meanwhile, the broader U.S. equity market provided little directional help, with the S&P 500 essentially flat, the Dow Jones modestly positive, and the NASDAQ slightly in the red during today’s session.
The combination of a meaningful insider purchase from a high-profile board member, the stock trading well below its 52-week high of $70.43, and the company’s ongoing strategic expansion initiatives — including a $350 million convertible notes offering to support international expansion and accelerate AI-driven platform investment — gave investors enough reason to step in, lifting HIMS to a session high of $25.39 and putting the stock on track for one of its stronger single-day performances in recent weeks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.